Select Page

PATHWISE INDUSTRY NEWS

Read important industry news with the latest articles on life sciences, manufacturing, and regulatory issues. 

FEBRUARY 2024 LIFE SCIENCE NEWS

Top 10 Takeaways from FDA’s Revised Quality System Requirements for Medical Devices 

“On February 2, 2024, the U.S. Food and Drug Administration (“FDA”) published a final rule1 to amend the current good manufacturing practice requirements for medical devices by harmonizing the existing requirements with ISO 13485:2016, the international consensus standard for device quality management systems used by regulatory authorities in many countries throughout the world. The revised requirements will be known as the Quality Management System Regulation (“QMSR”) … To reduce the regulatory burden on many global device manufacturers that must comply with both the QSR and ISO 13485, FDA is amending Part 820 to replace its QSR with the new QMSR that incorporates ISO 13485:2016 by reference. The QMSR also includes several additional definitions and requirements that clarify certain expectations and concepts from ISO 13485 and avoid potential inconsistencies with the FDCA and other applicable FDA requirements.”

READ THE FULL ARTICLE HERE

FDA modernizing pharmacovigilance oversight with AI tools

“To modernize its pharmacovigilance efforts, the US Food and Drug Administration (FDA) Office of Surveillance and Epidemiology (OSE) is using artificial intelligence (AI) to support the review of adverse event reports and is also piloting the standardization of Risk Evaluation and Mitigation Strategies (REMS) data to make it easier to use, said OSE Deputy Director Robert Ball. Speaking at DIA’s Global Pharmacovigilance and Risk Management Strategies Conference in Baltimore, MD, Ball said that OSE launched its Information Visualization Platform (InfoViP) an AI-based decision tool in 2022 to help the agency respond to the growing number of adverse event reports. The FDA receives more than 2 million reports a year, and this number is increasing every year. With these reports, FDA must decide whether to generate safety signals for marketed drugs.”

READ THE FULL ARTICLE HERE

FDA

FDA Urges Independent Verification of Third-Party Testing Data

“FDA recently published a statement reminding medical device study sponsors and medical device manufacturers to evaluate third party’s contracted to conduct performance testing, urging independent verification of all testing results before submission to the agency. “It is the responsibility of device firms to qualify third parties that generate data and to ensure that all information submitted to the FDA is truthful and accurate,” according to FDA.The agency said it has identified an increase in submissions containing unreliable data from third-party test labs, including numerous facilities in China and India. These third-party labs are reportedly creating fabricated, duplicated, or otherwise unreliable data for device submissions which, in-turn, has resulted in FDA’s inability to reach substantial equivalence determinations or authorize marketing for devices which include the data. Additionally, identifying the unreliable data could further call into question the entire files data integrity, the statement wrote.”

READ THE FULL ARTICLE HERE

How Trailblazing Manufacturers Are Using Generative AI in 2024

“Generative AI took the world by storm in 2023, from the classroom to the film studio, and the writer’s bench to the White House. Enterprises and creative industries worked to figure out how to leverage it in their operations, while classrooms and government entities struggled to govern its use. In 2024, manufacturers will increasingly apply it to their businesses and add it as a critical element in their digital toolboxes and as a powerful driver to their quality protocols. In fact, Gartner predicts that by 2026, more than 80% of enterprises will have used generative AI models and/or deployed them in production environments, up from less than 5% in early 2023.”

READ THE FULL ARTICLE HERE

JANUARY 2024 LIFE SCIENCE NEWS

Conducting Remote Regulatory Assessments-Questions and Answers; Revised Draft Guidance for Industry

FDA has revised and is reissuing the draft guidance in response to public comments and recent amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act). When finalized, this guidance will describe FDA’s current thinking regarding its use of remote regulatory assessments (RRAs). FDA has used RRAs to conduct oversight, mitigate risk, meet critical public health needs, and help maximize compliance of FDA-regulated products. This revised draft guidance provides answers to frequently asked questions regarding RRAs.

READ THE DRAFT GUIDANCE HERE

Inside the FDA’s plans for the largest reorganization in its history

It’s been a tough couple of years at the Food and Drug Administration.Inspired in part by the tumult over the headline-generating infant formula crisis in 2022, the agency is planning to overhaul its structure to make its inspections more efficient and effective, officials announced last week. At an Alliance for a Stronger FDA webinar Friday, agency leaders — including principal deputy commissioner Janet Woodcock — unveiled the agency’s reorganization plan. The multi-pronged approach involves reforming not only its human foods program but also its Office of Regulatory Affairs (ORA) as a whole. “This is the largest reorganization in FDA’s history,” said Michael Rogers, the FDA associate commissioner for regulatory affairs. “There’s a level of excitement within the agency.” The reorganization will affect some 8,000 people at the FDA, Rogers said, calling it a “huge culture change.”

READ THE FULL ARTICLE HERE

FDA

Warning letters: Same old, same old at FDA

Four warning letters posted earlier this year highlight that everything old is new again when it comes to enforcement problems for the US Food and Drug Administration. Specifically, FDA warned two companies for claiming their human cell and tissue products (HCT/P) can treat diseases or conditions without having an approved biologics license application (BLA), as seen in two recent warning letters. Additionally, the agency issued warning letters to two over-the-counter drug firms – one in the US and one in South Korea – for not testing incoming materials for contamination.
 FDA officials back in June 2021 said they were disappointed with the slow update of approvals of stem cell therapies and were stepping up their enforcement efforts against companies making unapproved therapies.

Read the Full Article Here!

5 FDA decisions to watch in the first quarter

Biotechnology is often described as an “innovation” industry, dependent on companies’ ability to invent and develop new medicines. By that metric, 2023 was a good year. The FDA’s main review office approved 55 novel drugs, the most since 2018, while the agency’s biologics division cleared 15 more. The clearances offer some counterbalance to a prolonged market downturn, during which the sector has struggled with a range of financial and regulatory headwinds.”

READ THE FULL ARTICLE HERE

 

DECEMBER 2023 LIFE SCIENCE NEWS

FDA compliance chiefs detail FY2023 trends, plans for FY2024

“Top US Food and Drug Administration (FDA) officials from the drug, biologics and medtech inspection offices said failure to maintain good manufacturing practices (GMPs) and marketing unapproved products are still the main reasons for issuing warning letters. FDA officials offered insight into their work over the past year and emerging trends at the 2023 enforcement conference hosted by the Food and Drug Law Institute (FDLI). They also discussed plans for the upcoming fiscal year, including cracking down on sponsors who fail to update data on ClinicalTrials.gov, as well as policing manufacturers of counterfeit and contaminated products.

READ THE FULL ARTICLE HERE

FDA

FDA Rounds Out 2023 with Advanced Manufacturing Technologies Designation Program Guidance

“As the close of 2023 approaches, the US Food and Drug Administration (FDA) has issued draft guidance detailing its new Advanced Manufacturing Technologies Designation Program, intended to facilitate the development and accelerate the review of drugs and biological products manufactured using an advanced manufacturing technology (AMT) that has been designated under the program. With the enactment of the 2022 omnibus spending bill, the US Congress mandated FDA to establish an AMT program for manufacturing methods that incorporate a novel technology or use an established technology in a unique way to produce a drug of equivalent or superior quality.”

READ THE FULL ARTICLE HERE

VIEW THE DRAFT GUIDANCE

https://www.fda.gov/media/174651/download

cGMP

​First version of the Union list of critical medicines agreed to help avoid potential shortages in the EU

“The European Commission (EC), the Heads of Medicines Agencies (HMA) and EMA have published the first version of the Union list of critical medicines. It contains more than 200 active substances of medicines for human use considered critical for healthcare systems across the EU/EEA, for which continuity of supply is a priority and shortages should be avoided. The European medicines regulatory network will prioritise critical medicines for EU-wide actions to strengthen their supply chain.”

READ THE FULL ARTICLE HERE

Apple Watch Ban Temporarily Halted

Apple’s efforts to halt a government-imposed ban on its newest Apple Watch models has bore fruit, at least temporarily. A ban on imports and sales of Apple Watches that use technology for reading blood-oxygen levels went into effect Tuesday. Apple promptly filed an appeal and asked the U.S. Court of Appeals for the Federal Circuit to halt the ban. The court granted the request Wednesday. The ban had impacted the company’s newest Apple Watches, including the Apple Watch Series 9 and Apple Watch Ultra 2. Apple has included the pulse oximeter feature in its watches starting with its Apple Watch Series 6 released in 2020. But the International Trade Commission (ITC) ruled in October that Apple infringed two patents owned by Masimo.”

READ THE FULL ARTICLE HERE

 

 

FDA drafts guidance outlining real-world evidence for medical device submissions

​”The 21st Century Cures Act, signed into law in 2016, created a framework for the FDA to use real-world evidence for regulatory decisions. In a final guidance issued a year later, the agency defined “real-world data” and “real-world evidence,” and provided an overview of how this information could be used to support its decisions on medical devices. In its latest draft guidance, the FDA clarified how it evaluates real-world data and provided expanded recommendations to medical device sponsors considering using real-world evidence to support regulatory submissions. For example, real-world data should be collected and processed in a “consistent and methodical manner,” to ensure reliability, the FDA said in the draft guidance. It should also include a sample size that is adequate to address the study question, and sponsors should provide a data audit trail.”

READ THE FULL ARTICLE HERE

 

INDUSTRY NEWS 2023- OUR TOP STORIES!!

The Future of Industrial AI in Manufacturing: A Manufacturing in 2030 Report

​“The growing role and importance of artificial intelligence in manufacturing cannot be overestimated. This pervasive technology, now coming into its own after many years of development and trial and error, is being incorporated into many technologies involved in the manufacturing process, including semiconductors, software applications and platforms, and communications equipment. It is important for the manufacturing industry to understand how AI may shape how factories and plants are run in the years ahead, how it will influence workforce strategies, what business benefits may attend the use of AI and what challenges must be faced and overcome to realize the potential of this technology. At the highest level, a global competition for AI dominance is underway, with manufacturing as a key player in the race. ”

READ THE FULL ARTICLE HERE

FDA to transition to electronic export documents for devices in 2024

“​Starting next year, the US Food and Drug Administration (FDA) will transition key export documents for medical devices from paper to digital format to reduce paperwork and streamline their workflow. Starting 2 January 2024, export documents for human medical devices that are regulated by the Center for Devices and Radiological Health (CDRH) will be issued electronically by FDA as downloadable PDFs from CDRH’s Export Certification Application and Tracking System (CECATS). The agency says the documents may then be validated by foreign governments and other entities who use the FDA Unified Registration and Listing Systems (FURLS) Export Certificate Validator (FECV) database. Companies can access the FECV online database from a web address or a QR code on the certificate.”

READ THE FULL ARTICLE HERE

medical device

In vitro diagnostic device regulation in Europe: Update on revisions

“The transition from complying with the EU IVDD 98/79/EC to meeting the requirements of the new EU IVDR 2017/746 involves a substantial regulatory framework for in vitro diagnostic (IVD) medical devices to ensure their safety and quality. The enhanced regulatory framework to speed up the market release includes, but is not limited to, additional scrutiny by a notified body, risk classification and conformity assessment, vigilance and market surveillance, and performance evaluation and performance studies.”

READ THE FULL ARTICLE HERE

Investigations

Under a new law, FDA submissions must prove that medical devices meet cybersecurity standards

Already this year, major medtech makers including BDInsulet and Zoll Medical have all alerted their customers to cybersecurity vulnerabilities in their medical devices that could potentially compromise sensitive health information or other personal data. Hoping to prevent any such breaches is the FDA, which will now require medical device makers to submit information about their cybersecurity efforts alongside applications for regulatory clearance of their devices. The new requirements went live Wednesday, as a $1.7 trillion federal omnibus spending bill took effect, though the FDA said in an accompanying guidance that it doesn’t intend to begin enforcing them until Oct. 1, at which point device makers will “have had sufficient time” to adjust to the guidelines.

READ THE FULL ARTICLE HERE

Combination Products Guidance

MDR transition delay approved by European Parliament and Council

“The European Parliament and Council today voted to approve a Medical Device Regulation (MDR) transition delay in an effort to avoid shortages. The move gives medical device manufacturers more time to certify their devices under the new MDR rules. I welcome today’s [European Parliament] vote to extend the transition period to new rules under the Medical Devices Regulation,” Commissioner for Health and Food Safety Stella Kyriakides said. “This will help give clarity to manufacturers and ensure that patients can access the essential medical devices they need. This is our top priority. The delay does not modify MDR’s current safety and performance requirements. Instead, it gives manufacturers more time to move from the old rules to the new requirements. It also removes the “sell-off” date that would have prevented the sale of products already on the market but still in the supply chain and not yet received by the user before the transition period ends.”

READ THE FULL ARTICLE

Combination Products Guidance

FDA Wants More Diversity in Clinical Trials

“The U.S. Food and Drug Administration says companies that produce drugs and other medical products should submit plans for how they will increase the number of Blacks and other underrepresented groups in clinical trials, the agency said Wednesday. Though racial and ethnic minorities are affected disproportionately by certain diseases, they are frequently underrepresented in medical research, the FDA said in a news release. Barriers to participation include suspicion of doctors, religion, health illiteracy, and lack of understanding of clinical trials.”

READ THE FULL ARTICLE HERE

The Intersection Of ISO 13485 And ISO 14971 Under The Proposed FDA QMSR

“The FDA proposed on Feb. 22, 2022, an update to the Quality System Regulation1 that was released in 1996. The proposal is to reference ISO 13485:2016 Medical devices — Quality management systems — Requirements for regulatory purposes,2 which is in its third edition since its 1996 release. The FDA QSR has not been updated since its 1996 release and needs to be brought to the current state of the art. Incidentally, the first edition of ISO 13485 was released at about the same time as the initial QSR, so 13485 has been updated twice while the FDA’s regulation has not been updated.”

READ THE FULL ARTICLE HERE